Innate Pharma

Regulatory Filings • Jun 3, 2010

INNATE PHARMA ANNOUNCES ITS PARTICIPATION TO MAJOR UPCOMING MEDICAL MEETINGS

Marseilles, France, June 3, 2010

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today that it will report clinical data for its two lead clinical drug candidate at the following June's medical meetings:

• At the Annual European Hematology Association ("EHA") Meeting, in Barcelona, Spain, on June 13, 2010:

Final data from the Phase I/II clinical trial evaluating IPH 1101 in combination with rituximab in follicular non-Hodgkin's lymphoma ("fNHL") patients (study "IPH 1101-202") will be subject to an oral presentation by Pr Jean-François Rossi (Head of Hemato-Oncology Department and Center of Clinical Investigation BT 509, University Hospital, Montpellier, France), co-lead investigator of the study (Abstract 1131, A phase I/II study of IPH1101, gamma delta T cell agonist, in combination with rituximab re-treatment, in patients with low grade follicular lymphoma).

Innate Pharma management will host a conference call to discuss these results on June 14, 2010. More details to connect to this conference call will be provided in the press release reporting the results and on the website.

• At the Annual American Society of Clinical Oncology ("ASCO") Meeting on June 5, 2010:

Updated interim data for the Phase I trial with IPH 2101 in Multiple Myeloma patients (study "IPH 2101-103"). The interim results will be subject to a poster presented by Don Benson, MD, PhD (Division of Hematology/Oncology, Ohio State Cancer Center, Columbus, OH), during the Lymphoma and Plasma Cell Disorders session (Abstract 8139, A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma).

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. The Company has two drug candidates currently in Phase II clinical trials. Two of its preclinical programs are out-licensed to Novo Nordisk A/S.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 79 employees as at March 30, 2010.

Learn more about Innate-Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus, which is available on the AMF website (http://www.amffrance.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Laure-Hélène Mercier Director, Investor Relations Phone: +33 (0)4 30 30 30 87 Mobile: +33 (0)6 64 18 99 59 investors@innate-pharma.com caroline@alizerp.com

Innate Pharma Alize Public Relations Caroline Carmagnol Phone: +33 (0) 1 42 68 86 43

IPH next medical meetings Page 2/2